All lobbying filings

MEHLMAN CONSULTING, INC.

MEHLMAN CONSULTING, INC. filed a Q2 report for ASSOCIATION OF ACCESSIBLE MEDICINES on July 17, 2026, reporting $60,000 in lobbying income.

Lobbying for ASSOCIATION OF ACCESSIBLE MEDICINES · Trade Association

All filings by MEHLMAN CONSULTING, INC. · Everything ASSOCIATION OF ACCESSIBLE MEDICINES has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 17, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Medicare/Medicaid

Issues related to generic medicines.

Health Issues

Issues related to generic and biosimilar medications.

Pharmacy

Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling.

Bills named in this filing 7

S. 1040
Drug Competition Enhancement Act
H.R. 5526
Biosimilar Red Tape Elimination Act
S. 1954
Biosimilar Red Tape Elimination Act
H.R. 3269
ETHIC Act
S. 43
Skinny Labels, Big Savings Act
H.R. 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S. 1302
Increasing Transparency in Generic Drug Applications Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.